Category Archives: Ulcerative Colitis

Thanks to a growing demand for convenience, the number of services that offer online meal delivery kits has exploded in recent years. Even before the COVID-19 pandemic, the number of people using meal kits grew by 36 percent from 2017 to 2018, according to Nielsen data, with another 23 percent of households saying they were open to purchasing a meal kit within six months. Meal delivery kits can be great for people who lack time to shop for food and cook, says Kelly Kennedy, a registered dietitian nutritionist with Everyday Health Continue reading →

December 15, 2020 11:00 ET | Source: Crohn's and Colitis Canada multilang-release TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Crohns and Colitis Canada is delighted to award over $1.2 million in new grants through its Grants-in-Aid of Research and Innovations in IBD Research grant programs. With funds distributed among five principal investigators and their teams, the grants will support novel research projects focused on Crohns disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD). Continue reading →

When she was nine years old, Emma Haist started having bad cramps and losing weight. She would come home from school and lie on the couch, sleeping through dinner until the next morning. At first, her family doctor thought she might be allergic to dairy or glucose Continue reading →

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ --Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD), today announced FDA acceptance of its Investigational New Drug Application (IND) for PRA023 and that dosing has commenced in a Phase 1a clinical study in normal healthy volunteers. Continue reading →

December 18, 2020 02:00 ET | Source: Hofseth Biocare ASA NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") on 4 December 2020 regarding the approval by the Financial Supervisory Authority of Norway of the Company's prospectus dated 3 December 2020 (the "Prospectus") prepared in connection with inter alia, a subsequent offering of new shares in the Company (the "Offer Shares"). The subscription period in the Subsequent Offering will end today and Subscription Rights that are not used to subscribe for Offer Shares before 16:30 hours (CET) today, on 18 December 2020, will have no value and will lapse without compensation to the holder Continue reading →

Written by Hattie Gladwell on December 15, 2020 Fact checked by Jennifer Chesak We need to stop starting every new year by setting these unreachable standards for ourselves. Each year, my social media feeds are filled with New Years resolutions. Continue reading →

NEW YORK, Dec. Continue reading →

A GROUP of friends who all suffer from Crohns or Ulcerative Colitis took part in a 10km walk last month to raise funds for charity. Charlotte, Toni, Alice and Mike took on the challenge on October 25 with support from their family and friends. The team of four raised 1,085 for Crohns and Colitis UK - a charity which is dedicated to helping people with Crohn's disease, ulcerative colitis, and other forms of inflammatory bowel disease to live a better quality of life and ultimately find a cure. Continue reading →

DGAP-News: ABIVAX / Key word(s): Study 30.11.2020 / 19:00 The issuer is solely responsible for the content of this announcement. Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis PARIS, November 30, 2020 - 7:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today the completion of recruitment for its Phase 2b induction study for the lead candidate ABX464 for the treatment of patients with moderate-to-severe ulcerative colitis. Continue reading →

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the companys Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils. During active flares of ulcerative colitis, neutrophils migrate into the submucosa and lumen of the colon where they contribute to tissue damage by releasing a cocktail of destructive enzymes, DNA, histones and pro-inflammatory mediators. Continue reading →